title: Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study.
authors.affiliation: Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
authors.forename: S W
authors.initials: SW
authors.lastname: Youn
authors.affiliation: Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
authors.forename: B R
authors.initials: BR
authors.lastname: Kim
authors.affiliation: Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.|SMG-SNU Boramae Medical Center, Seoul, Korea.
authors.forename: S
authors.initials: S
authors.lastname: Cho
authors.affiliation: Department of Dermatology, Chung-Ang University Hospital, Seoul, Korea.
authors.forename: S J
authors.initials: SJ
authors.lastname: Seo
authors.affiliation: Department of Dermatology, Ajou University Medical Center, Suwon, Korea.
authors.forename: E S
authors.initials: ES
authors.lastname: Lee
authors.affiliation: Department of Dermatology, Gachon University Gil Hospital, Incheon, Korea.
authors.forename: J Y
authors.initials: JY
authors.lastname: Roh
authors.affiliation: Department of Dermatology, Inha University Hospital, Incheon, Korea.
authors.forename: G S
authors.initials: GS
authors.lastname: Choi
authors.affiliation: Department of Dermatology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: M G
authors.initials: MG
authors.lastname: Lee
mesh_terms: D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D009260:Nail Diseases / Q000188:drug therapy* / Q000209:etiology; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000069549:Ustekinumab / Q000627:therapeutic use*
chemical_list: D003879:Dermatologic Agents; D000069549:Ustekinumab